Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Beta Bionics (BBNX) EBITDA Margin (2024 - 2026)

Beta Bionics' EBITDA Margin history spans 3 years, with the latest figure at 81.06% for Q1 2026.

  • On a quarterly basis, EBITDA Margin rose 8040.0% to 81.06% in Q1 2026 year-over-year; TTM through Mar 2026 was 60.57%, a 4071.0% increase, with the full-year FY2025 number at 72.68%, up 1151.0% from a year prior.
  • EBITDA Margin hit 81.06% in Q1 2026 for Beta Bionics, down from 41.77% in the prior quarter.
  • Over the last five years, EBITDA Margin for BBNX hit a ceiling of 41.77% in Q4 2025 and a floor of 161.47% in Q1 2025.
  • Historically, EBITDA Margin has averaged 83.18% across 3 years, with a median of 81.06% in 2026.
  • Biggest five-year swings in EBITDA Margin: crashed -6419bps in 2025 and later surged 8040bps in 2026.
  • Tracing BBNX's EBITDA Margin over 3 years: stood at 88.56% in 2024, then surged by 53bps to 41.77% in 2025, then tumbled by -94bps to 81.06% in 2026.
  • Business Quant data shows EBITDA Margin for BBNX at 81.06% in Q1 2026, 41.77% in Q4 2025, and 51.39% in Q3 2025.